
    
      The study staff will employ MEMS caps to prospectively measure adherence to ritonavir and its
      accompanying protease inhibitor over 24 weeks of follow-up. Paired sample t-tests will be
      employed to compare adherence to the two agents, and secondary analyses will be conducted to
      evaluate the chronologic concordance of ritonavir and accompanying protease inhibitor dosing.
    
  